- Home
- ITOC vs ASBP Comparison
ITOC vs ASBP Comparison
Compare ITOC & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ITOC | ASBP |
|---|---|---|
| Founded | 1998 | 2021 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0M | 7.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ITOC | ASBP |
|---|---|---|
| Price | $0.29 | $0.88 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.7K | ★ 167.8K |
| Earning Date | 03-20-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.05 |
| 52 Week High | $0.65 | $2.45 |
Technical Indicators
Market Signals| Indicator | ITOC | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 31.00 | 39.61 |
| Support Level | N/A | $0.12 |
| Resistance Level | $0.38 | $0.88 |
| Average True Range (ATR) | 0.03 | 0.15 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 21.85 | 35.77 |
Price Performance
Historical ComparisonAbout ITOC iTonic Holdings Ltd Class A Ordinary Shares
iTonic Holdings Ltd through its subsidiary, focuses on healthcare solutions for brachytherapy, a targeted radiation therapy used in cancer treatment. Its product, Beijing Feitian's Treatment Planning System, helps ensure safe and effective brachytherapy using radioactive sources inside the patient to kill cancer cells and shrink tumors.
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.